Clinical Trial

Breast Cancer: Axillary Conservation After Neoadjuvant Chemotherapy in Micro Metastatic Sentinel Lymph Nodes.

Study acronym: NEONOD2
Recruiting
View on ClinicalTrials.gov →
Summary
Italian multicentric non inferiority clinical study to verify whether the omission of axillary lymph node intervention in patients with SLN (Sentinel Lymph Nodes) ypN1mi after NAC (Neo Adiuvant Chemotherapy) does not lead to a significant deterioration in survival or in the risk of regional or distant recurrence, compared to patients with negative SLN (SLN ypN0) after NAC ,where the omission of axillary treatment is currently the standard treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2019-07-12; most recent amendment 2021-04-15.
Trial Details
NCT Number NCT04019678
Lead Sponsor Istituto Clinico Humanitas
Conditions Breast Cancer
Enrollment 850 participants
Start Date 2019-06-21
Primary Completion 2027-06-21 (estimated)
Study Completion 2027-06-21 (estimated)
Updated on ClinicalTrials.gov 2021-04-19